Hepatitis E Virus Infection in Iranian Kidney-Transplant Patients by Kamar, Nassim
KOWSAR
Journal home page: www.HepatMon.com
Hepatitis E Virus Infection in Iranian Kidney-Transplant Patients
 Nassim  Kamar  1* 
1 Department of Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France 
* Corresponding author: Nassim Kamar, Department of Nephrology, Dialy-
sis and Organ Transplantation, CHU Rangueil, TSA 50032, 31059 Toulouse 
Cedex 9, France. Tel: +33-561322335, Fax: +33-561323989, E-mail: kamar.n@
chu-toulouse.fr
DOI: 10.5812/kowsar.1735143X.791
Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
ARTICLE INFO
Article history:
Received: 23 Oct 2011
Revised: 06 Nov 2011
Accepted: 12 Nov 2011
Keywords:
 Hepatitis E 
 Kidney Transplantation
 Patients
Article type:
Letter to Editor     
  Please cite this paper as: 
Kamar N. Hepatitis E Virus Infection in Iranian Kidney-
Transplant Patients. Hepat Mon. 2011;11(11):927-8. DOI: 10.5812/
kowsar.1735143X.791
  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
Hepat Mon.2011;11(11):927-928. DOI: 10.5812/kowsar.1735143X.791
Dear Editor,
Hepatitis E virus infection is an endemic disease in de-
veloping and industrialized countries (1),and is respon-
sible for acute and chronic hepatitis. Genotype 1 is more 
prevalent in developing countries, whereas genotype 3 is 
more common in developed countries (1). Chronic geno-
type 3 HEV infection can occur in solid-organ transplant 
patients (2), hematological patients who receive chemo-
therapy (3), and HIV-positive patients (4). In the past sev-
eral years, HEV infection in organ transplant patients has 
garnered much interest. After kidney transplantation, 
HEV-related liver ﬁbrosis can lead rapidly to cirrhosis (5). 
The use of tacrolimus, rather than cyclosporine A, and a 
low platelet count at HEV diagnosis have been identiﬁed 
as predictive factors for chronic HEV infection (6). How-
ever, decreased immunosuppressant dose can result in 
HEV clearance in nearly one-third of patients (6). In ad-
dition, ribavirin monotherapy can be eﬃcacious in treat-
ing chronic HEV infection (7).
In this issue of Hepatitis Monthly, Khameneh et al. de-
termined the prevalence of anti-HEV IgG in 91 randomly 
selected Iranian kidney transplant patients (8). The HEV 
seroprevalence was 30.8%, although there was poor sen-
sitivity and speciﬁcity between HEV serological assays 
(9). However, this study on seroprevalence in an Iranian 
kidney transplant population is a ﬁrst step toward im-
proving the assessment of HEV infection in this setting. 
Unfortunately, as discussed by the authors, HEV RNA was 
not measured in this study. Consequently, the authors 
were unable to determine whether some patients devel-
oped chronic hepatitis—a signiﬁcant shortcoming, be-
cause 45.1% of patients had unexplained increases in liver 
function tests (8). The measurement of HEV genotype 
may also be valuable, because, similar to what has been 
observed in Europe, Khameneh et al. found more positive 
HEV serologies in older patients (8).
In summary, Khamaneh et al. noted a high seropreva-
lence rate of HEV in an Iranian kidney transplant popula-
tion. Further studies are needed to evaluate the impact of 
HEV infection in this population.
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